uniQure (QURE)
NasdaqMarket Closed
uniQure N.V. is a biotechnology company focused on gene therapies for severe genetic and neurological diseases. The company develops treatments designed to address the underlying cause of illness by delivering functional genetic material to targeted cells, most notably through adeno-associated virus, or AAV, vector technology. Its work sits within a specialist area of medicine where a single treatment can potentially produce long-lasting therapeutic benefit, but where clinical development, manufacturing, and regulatory review are highly complex.
The company’s pipeline spans several disease areas with significant unmet need. Its most closely watched programmes include therapies for Huntington’s disease, temporal lobe epilepsy, Fabry disease, amyotrophic lateral sclerosis linked to SOD1 mutations, and haemophilia B. uniQure also maintains research-stage programmes aimed at expanding the use of its gene therapy platform into additional indications.
uniQure is known for combining internal research capabilities with external collaborations. In cardiovascular disease, it works with Bristol Myers Squibb, reflecting the broader industry trend of large pharmaceutical companies partnering with specialised gene therapy developers. The company’s operations cover discovery, vector engineering, clinical development, and manufacturing expertise, all of which are central to advancing gene therapies from laboratory research into human trials.
For investors, uniQure represents exposure to the high-risk, high-potential end of the biotechnology market. Its value is closely tied to clinical trial outcomes, regulatory decisions, durability of treatment effects, and the company’s ability to manufacture complex therapies at scale.
Last updated
- Market Cap
- $3,029,924,876
- P/E
- —
- P/FCF
- —
- P/S
- 162.27
- Enterprise Value
- $2,667,044,876
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- PAASHEUVELWEG 25A, AMSTERDAM, 1105 BP
5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX
uniQure Announces Pricing of Upsized $225 Million Public Offering
What made uniQure stock nearly double on Wednesday?
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman
INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data
UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE
UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors
ROSEN, A TRUSTED AND LEADING INVESTOR RIGHTS FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Driven Brands Holdings Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and 39% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $3,029,924,876
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $2,667,044,876
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 9.35
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 162.27
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -15.27
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 142.84
- EPS
- -3.64
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$161,452,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -77.83%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -25.6%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.15
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 10.01
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 10.01
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 4.96
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $1,837,695
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 43.68
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 5.84M | 3.56M | 5.57M | 3.7M | 5.26M |
| Cost of revenue | 350K | 219K | 435K | 398K | 656K |
| Gross profit | 5.49M | 3.34M | 5.13M | 3.3M | 4.61M |
| Operating income | -52.2M | -45.72M | -38.71M | -52.55M | -43.87M |
| EBITDA | -47.3M | -42.76M | -35.74M | -48.91M | -40.24M |
| Net income | -81.06M | -53.54M | -37.09M | -80.53M | -37.72M |
| Income taxes | 1.84M | 488K | -3.92M | 8.63M | 425K |
| Interest expense | -14.37M | -14.03M | -14.57M | -16.72M | -15.59M |
| Other operating expenses | 6.36M | -181K | -12.56M | 2.04M | -412K |
| Total operating expenses | 57.69M | 49.06M | 43.84M | 55.85M | 48.47M |
| Basic EPS | -1.22 | -0.85 | -0.58 | -1.38 | -0.69 |
| Diluted EPS | -1.22 | -0.85 | -0.58 | -1.38 | -0.69 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 985.1M | 778.71M | 824.91M | 888.38M | 584.89M |
| Total liabilities | 661.05M | 629.36M | 626.01M | 659.64M | 588.89M |
| Total equity | 324.05M | 149.34M | 198.9M | 228.75M | -4M |
| Cash & equivalents | 413.03M | 139.99M | 80.24M | 597.06M | 253.78M |
| Current assets | 834.27M | 615.74M | 655.99M | 716.19M | 408.57M |
| Current liabilities | 83.35M | 59.2M | 62.92M | 100.63M | 40.93M |
| Accounts payable | 4.98M | 4.4M | 5.17M | 6.23M | 5.54M |
| Receivables | 13.69M | 12.61M | 12.94M | 11.62M | 13.06M |
| Inventories | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 24.59M | 24.81M | 25.36M | 25.33M | 25.34M |
| Long-term debt | 50.15M | 49.94M | 49.7M | 51.88M | 507.1M |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | -28.58M | -38.24M | -77.57M | -16.4M | -39.9M |
| Investing cash flow | 53.26M | 98.56M | -441.37M | 26.58M | 73.07M |
| Financing cash flow | 249.12M | 550K | 2.45M | 332.24M | 44K |
| Change in cash | 273.03M | 59.74M | -516.75M | 343.28M | 36.61M |
| Net income | -81.06M | -53.54M | -37.09M | -80.53M | -37.72M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — uniQure N.V. | View Filing | |
| edgar index | SCHEDULE 13G — uniQure N.V. | View Filing | |
| edgar index | 8-K — uniQure N.V. | View Filing | |
| edgar index | 10-Q — uniQure N.V. | View Filing | |
| edgar index | S-8 — uniQure N.V. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — uniQure N.V. | View Filing | |
| edgar index | SCHEDULE 13G — uniQure N.V. | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Abi-Saab Walid | View Filing | |
| form 4 | Form 4 — Abi-Saab Walid | View Filing | |
| form 4 | Form 4 — Abi-Saab Walid | View Filing | |
| form 4 | Form 4 — Abi-Saab Walid | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| form 4 | Form 4 — Abi-Saab Walid | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| edgar index | 424B5 — uniQure N.V. | View Filing | |
| edgar index | 8-K — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 8-K — uniQure N.V. | View Filing | |
| edgar index | 424B5 — uniQure N.V. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 4 — uniQure N.V. | View Filing | |
| edgar index | 8-K — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| edgar index | 144 — uniQure N.V. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Kaye Jack | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Balachandran Madhavan | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing | |
| form 4 | Form 4 — Kapusta Matthew C | View Filing |